Mycobacterial infections including Mycobacterium tuberculosis have been increasing globally. The additional prevalence of multidrug-resistant (MDR-TB) strains and extensively drug-resistant tuberculosis (XDR-TB) stimulate an urgent need for the development of new drugs for the treatment of mycobacterial infections. It is very important to test the antimicrobial activity of novel compounds because they can be used in new with antimycobacterial drug formulation. Studies have shown that Mycobacterium smegmatis can be used in Minimum Inhibitory Concentration (MIC) assays with the advantage of rapidly and safely screen anti-tubercular compounds. This paper presents an evaluation of potential mycobacteriological compounds derived from inorganic synthesis and their microbiological performance along and in conjunction with Trimethoprim. Antimicrobial activity experiments were carried out by using the microdilution technique in broth to evaluate the sensibility against M. smegmatis. MIC values were between 0.153 and 4.88 μg/ml for the compounds tested. Tests of interaction between drugs were made by the method of Fractional Inhibitory Concentration Index (FICI). The compound [Au (sulfatiazolato)(PPh₃)] showed synergism FICI = 0.037 and was evaluated by isobols.